https://www.andorrahealthwatch.com/article/906845683-ascentage-pharma-to-present-four-promising-preclinical-studies-demonstrating-the-potential-of-combination-therapies-at-american-association-for-cancer Andorra Health Watch en PressRelease 2026-04-20T00:00:00+00:00 Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting https://ml.globenewswire.com/media/b9623a51-a13b-4b80-8152-61d5014f4a0a/small/2025-11-12-ascentage-600x600-png.png https://www.andorrahealthwatch.com/article/906845652-sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026 Andorra Health Watch en PressRelease 2026-04-19T23:45:00+00:00 Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 https://ml.globenewswire.com/media/b29d64ff-a5d8-41ff-9d46-e0e332cc7f28/small/image001-png.png https://www.andorrahealthwatch.com/article/906841121-monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026 Andorra Health Watch en PressRelease 2026-04-19T23:00:00+00:00 Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 https://ml.globenewswire.com/media/f8cee181-5ae9-4a02-84f5-6e35affbb72b/small/monopartherapeuticsinc-png.png https://www.andorrahealthwatch.com/article/906832668-kimmtrak-doubles-the-likelihood-of-being-alive-at-five-years-for-first-line-hla-a-02-01-patients-with-metastatic-uveal-melanoma Andorra Health Watch en PressRelease 2026-04-19T22:00:00+00:00 KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma https://ml-eu.globenewswire.com/media/bcaafaab-2536-4b4b-899c-9913925b6e4b/small/immunocore-logo-2018.png https://www.andorrahealthwatch.com/article/906832675-xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onset-seizures-at-2026-aan-annual-meeting Andorra Health Watch en PressRelease 2026-04-19T22:00:00+00:00 Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting https://ml.globenewswire.com/media/505b89d3-dfd1-46e8-bc3b-3c9c699ef7ec/small/xenon-logo-tm-full-color-250x80px-png.png https://www.andorrahealthwatch.com/article/906816139-transactions-in-zealand-pharma-shares-and-or-related-securities-by-persons-discharging-managerial-responsibilities-and-or-their-closely-associated Andorra Health Watch en PressRelease 2026-04-19T20:05:00+00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png https://www.andorrahealthwatch.com/article/906816100-zealand-pharma-launches-long-term-incentive-programs-for-zealand-pharma-s-board-of-directors-corporate-management-and-employees-for-2026 Andorra Health Watch en PressRelease 2026-04-19T20:00:00+00:00 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png https://www.andorrahealthwatch.com/article/906800541-revolution-medicines-to-present-updated-phase-1-clinical-data-for-zoldonrasib-in-patients-with-previously-treated-kras-g12d-non-small-cell-lung-cancer Andorra Health Watch en PressRelease 2026-04-19T18:00:00+00:00 Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.andorrahealthwatch.com/article/906786185-molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin Andorra Health Watch en PressRelease 2026-04-19T16:00:00+00:00 Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 https://ml.globenewswire.com/media/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb/small/molecularpartners-logo-jpg.jpg https://www.andorrahealthwatch.com/article/906641487-herz-p1-smart-oximeter-claims-evaluated-best-pulse-oxygen-monitor-device-on-the-market-with-clinical-grade-accuracy Andorra Health Watch en PressRelease 2026-04-18T23:25:01+00:00 Herz P1 Smart Oximeter Claims Evaluated: Best Pulse Oxygen Monitor Device on the Market with Clinical-Grade Accuracy https://zingfast.com/wp-content/uploads/2026/04/Herz-P1-Smart-Oximeter.jpg https://www.andorrahealthwatch.com/article/906622464-vigor-boost-gummies-claims-evaluated-the-forcevital-male-enhancement-formula-under-investigation Andorra Health Watch en PressRelease 2026-04-18T21:34:15+00:00 Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation https://zingfast.com/wp-content/uploads/2026/04/Vigor-Boost-Gummies.jpg https://www.andorrahealthwatch.com/article/906601019-slimleaf-claims-evaluated-the-fitburn-formula-using-slim-leaf-ingredients-for-weight-loss Andorra Health Watch en PressRelease 2026-04-18T20:10:35+00:00 SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss https://zingfast.com/wp-content/uploads/2026/04/SlimLeaf.jpg https://www.andorrahealthwatch.com/article/906577634-pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the Andorra Health Watch en PressRelease 2026-04-18T17:31:00+00:00 Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/e31d4c37-738e-4662-861d-675c8c564317/medium/figure-1.jpg https://www.andorrahealthwatch.com/article/906577555-theriva-biologics-anuncia-la-pr-xima-presentaci-n-de-datos-adicionales-del-ensayo-cl-nico-virage-de-fase-2b-del-vcn-01-para-el-c-ncer-de-p-ncreas Andorra Health Watch en PressRelease 2026-04-18T17:17:08+00:00 Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 https://ml.globenewswire.com/media/ed41908b-8799-4f56-bc3c-acff4f4872eb/small/tovx-logo-jpg.jpg https://www.andorrahealthwatch.com/article/906552980-maps-welcomes-federal-action-to-advance-science-driven-psychedelic-research-and-policy Andorra Health Watch en PressRelease 2026-04-18T15:34:50+00:00 MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg https://www.andorrahealthwatch.com/article/906501406-press-release-escmid-sanofi-s-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-head-to-head-study Andorra Health Watch en PressRelease 2026-04-18T10:00:00+00:00 Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.andorrahealthwatch.com/article/906501531-communiqu-de-presse-escmid-le-nuvaxovid-vaccin-contre-la-covid-19-de-sanofi-a-montr-une-meilleure-tol-rance-que-le-mnexspike-dans-une-tude Andorra Health Watch en PressRelease 2026-04-18T10:00:00+00:00 Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe   https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.andorrahealthwatch.com/article/906476191-vigosurge-claims-evaluated-analyzing-the-ingredients-benefits-side-effects-risk-and-customer-complaints Andorra Health Watch en PressRelease 2026-04-18T08:34:39+00:00 VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints https://zingfast.com/wp-content/uploads/2026/04/VigoSurge.jpg https://www.andorrahealthwatch.com/article/906451168-argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgart-use-across-mg-and-cidp Andorra Health Watch en PressRelease 2026-04-18T05:00:00+00:00 argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png